IP Library › Patent Application 13500589
Patent Application
App. No. 13/500,589

METHODS OF TREATING DISEASES WITH PROANTHOCYANIDIN OLIGOMERS SUCH AS CROFELEMER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/500,589
Abstract

Disclosed herein are methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer. Also disclosed is the anti-secretory effect of crofelemer on Calcium-activated chloride channels (CaCC) and Cystic fibrosis transmembrane conductance regulator (CFTR).

Claims (13)

1 . A method of modulating Cl − secretion in a cell, comprising contacting a cell comprising a calcium-activated chloride channel (CaCC) with an effective amount of crofelemer.

2 . The method of claim 1 wherein the CaCC is TMEM16A CaCC.

3 . A The method of claim 1 , wherein the cell further comprises one or more of a cystic fibrosis transmembrane conductance regulator (CFTR) and an epithelial sodium channel (ENaC).

4 . A method of modulating Na + secretion of a cell, comprising contacting a cell comprising a Na + channel with an effective amount of crofelemer.

5 . The method of claim 4 wherein the Na + channel is epithelial sodium channel (ENaC).

6 - 32 . (canceled)

33 . The method of claim 1 , wherein contacting the cell comprises contacting an intestinal cell or a bronchial cell.

34 . The method of claim 1 , wherein the effective amount of crofelemer is about 1-1,000 μM.

35 . The method of claim 1 , wherein the effective amount of crofelemer comprises from about 10 to about 2,000 mg of crofelemer.

36 . The method of claim 4 , wherein the effective amount of crofelemer comprises from about 10 to about 2,000 mg of crofelemer.

37 . A method of treating a patient suffering from a calcium-activated chloride channel (CaCC) chanelpathy disorder comprising administering an effective amount of a pharmaceutical composition comprising crofelemer to the patient.

38 . The method of claim 37 , wherein the CaCC channelpathy disorder is selected from a group consisting of Cystic fibrosis, Erythromelalgia, Hyperkalemic periodic paralysis, Hypokalemic periodic paralysis, Long QT syndrome, Short QT syndrome, Malignant hyperthermia, Myotonia cogenita, and Neuromytonia.

39 . The method of claim 37 , wherein the pharmaceutical composition comprises from about 10 to about 2,000 mg crofelemer.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2018
From: HERCULES CAPITAL, INC.
To: JAGUAR HEALTH, INC.
Reel/Frame 045496/0039 →
SECURITY INTEREST Recorded Nov 22, 2017
From: NAPO PHARMACEUTICALS, INC.
To: KINGDON CAPITAL MANAGEMENT, L.L.C.
Reel/Frame 044497/0954 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 12, 2016
From: JAGUAR ANIMAL HEALTH, INC.
To: HERCULES TECHNOLGY GROWTH CAPITAL, INC., AS AGENT
Reel/Frame 037809/0161 →
SECURITY AGREEMENT Recorded Apr 2, 2015
From: GLYCYX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 035364/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2014
From: CHATURVEDI, PRAVIN
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 032861/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2012
From: VERKMAN, ALAN; TRADTRANTIP, LUKMANEE; NAMKUNG, WAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 028005/0126 →